CTOs on the Move

Home Advantage

www.home-adv.com

 
Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.home-adv.com
  • 13800 Coppermine Rd Ste 300
    Herndon, VA USA 20171
  • Phone: 800.297.2180

Executives

Name Title Contact Details

Similar Companies

Sanford Jackson Medical Center

Sanford Jackson Medical Center is a Jackson, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LIGNO TECH USA

LIGNO TECH USA is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

clarient

clarient is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omicia

Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 300 academic and clinical institutions including the NIH, the University of Oxford, the University of Cambridge, Seattle Children’s Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.